Objective: The feasibility of the conduction system pacing (CSP) upgrade as an alternative modality to the traditional biventricular pacing (BiVP) upgrade in patients with pacemaker-induced cardiomyopathy (PICM) remains uncertain. This study sought to compare two modalities of CSP (His bundle pacing (HBP) and left bundle branch pacing (LBBP)) with BiVP and no upgrades in patients with pacing-induced cardiomyopathy.Methods: This retrospective analysis comprised consecutive patients who underwent either BiVP or CSP upgrade for PICM at the cardiac department from 2017 to 2021. Patients with a follow-up period exceeding 12 months were considered for the final analysis.Results: The final group of patients who underwent upgrades included 48 individuals: 11 with BiVP upgrades, 24 with HBP upgrades, and 13 with LBBP upgrades. Compared to the baseline data, there were significant improvements in cardiac performance at the last follow-up. After the upgrade, the QRS duration (127.81 ± 31.89 vs 177.08 ± 34.35 ms, p < 0.001), NYHA class (2.28 ± 0.70 vs 3.04 ± 0.54, p < 0.05), left ventricular end-diastolic diameter (LVEDD) (54.08 ± 4.80 vs 57.50 ± 4.85 mm, p < 0.05), and left ventricular ejection fraction (LVEF) (44.46% ± 6.39% vs 33.15% ± 5.25%, p < 0.001) were improved. There was a noticeable improvement in LVEF in the CSP group (32.15% ± 3.22% vs 44.95% ± 3.99% (p < 0.001)) and the BiVP group (33.90% ± 3.09% vs 40.83% ± 2.99% (p < 0.001)). The changes in QRS duration were more evident in CSP than in BiVP (56.65 ± 11.71 vs 34.67 ± 13.32, p < 0.001). Similarly, the changes in LVEF (12.8 ± 3.66 vs 6.93 ± 3.04, p < 0.001) and LVEDD (5.80 ± 1.71 vs 3.16 ± 1.35, p < 0.001) were greater in CSP than in BiVP. The changes in LVEDD (p = 0.549) and LVEF (p = 0.570) were similar in the LBBP and HBP groups. The threshold in LBBP was also lower than that in HBP (1.01 ± 0.43 vs 1.33 ± 0.32 V, p = 0.019).Conclusion: The improvement of clinical outcomes in CSP was more significant than in BiVP. CSP may be an alternative therapy to CRT for patients with PICM. LBBP would be a better choice than HBP due to its lower thresholds.
16 December 2024 in Reviews in Cardiovascular Medicine
Existing techniques for pacing the right ventricle and providing cardiac resynchronization therapy through biventricular pacing are not effective in restoring damage to the conduction system. Therefore, the need for new pacing modalities and techniques with more sensible designs and algorithms is justified. Although the benefits of conduction system pacing (CSP), which mainly include His bundle pacing (HBP) and left bundle branch area pacing (LBBAP), are evident in patients who require conduction system recuperation, the critical criteria for left CSP remain unclear, and the roles of different pacing modalities of CSP for cardiac resynchronization are not definite. In this review, we aimed to highlight the advantages of different CSP options, current advancement in the surgical devices, and future directions.
Background: The relationship between conduction system pacing (CSP) and the incidence of atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains uncertain. This study aims to investigate the occurrence of atrial high-rate episodes (AHREs) following CSP in patients with HFpEF, in comparison to right ventricular pacing (RVP).Methods: Patients with HFpEF who received dual-chamber pacemakers for atrioventricular block were retrospectively enrolled from January 2018 to January 2023. Both new-onset and progressive AHREs were recorded, along with other clinical data, including cardiac performance and lead outcomes.Results: A total of 498 patients were enrolled, comprising 387 patients with RVP and 111 patients with CSP, with a follow-up duration of 44.42 ± 10.41 months. In patients without a prior history of AF, CSP was associated with a significantly lower incidence of new-onset AHREs when the percentage of ventricular pacing was ≥20% (9.52% vs. 29.70%, P = 0.001). After adjusting for confounding factors, CSP exhibited a lower hazard ratio for new-onset AHREs compared to RVP (HR 0.336; [95% CI: 0.142–0.795]; P = 0.013), alongside left atrial diameter (LAD) (HR 1.109; [95% CI: 1.048–1.173]; P < 0.001). In patients with a history of AF, the progression of AHREs in CSP and RVP did not differ significantly (32.35% vs. 34.75%, P = 0.791). Cardiac performance metrics, including left ventricular end-diastolic diameter (LVEDD) (49.09 ± 4.28 mm vs. 48.08 ± 4.72 mm; P = 0.015), LAD (40.68 ± 5.49 mm vs. 39.47 ± 5.24 mm; P = 0.001), and NYHA class (2.31 ± 0.46 vs. 1.59 ± 0.73; P < 0.001), improved obviously following CSP, while LVEDD (48.37 ± 4.57 mm vs. 49.30 ± 5.32 mm; P < 0.001), LAD (39.77 ± 4.58 mm vs. 40.83 ± 4.80 mm; P < 0.001), NYHA class (2.24 ± 0.43 vs. 2.35 ± 0.83; P = 0.018), and left ventricular ejection fraction (LVEF) (57.41 ± 2.42 vs. 54.24 ± 6.65; P < 0.001) deteriorated after RVP.Conclusion: Our findings suggest that CSP may be associated with improvements in cardiac performance and a reduction in new-onset AHREs compared to RVP in patients with HFpEF. However, prospective randomized trials are anticipated to confirm these potential benefits.
A 70-year-old man with severe valvular cardiomyopathy, permanent atrial fibrillation (AF) with a slow ventricular response, and transient atrioventricular (AV) block, was admitted to our center for severe heart failure and recurrent presyncope. While hospitalized, the coronary computed tomography angiography (CTA) showed huge atriums. We tried His bundle pacing (HBP). HB potential was observed at site A, and the His-ventricular (HV) interval was 68 ms. The duration from the stimulus signal to the onset of paced QRS (S-QRSonset) at site A was 232 ms when pacing at 60 beats per minute (BPM) with the pacing threshold of 2.0 V/0.5 ms. The S-QRSonset was longer than the HV interval and had a notable and progressive prolongation from 252 ms to 456 ms during the pacing at 90 BPM. Then, we pushed another lead a little forward, and the S-QRSonset shortened back to 68 ms, and the paced QRS morphology was the same as the intrinsic QRS morphology with the pacing threshold of 1.5 V/0.5 ms. The progressively prolonged S-QRSonset demonstrated a Wenckebach phenomenon (WP), a well-known electrophysiological characteristic of the AV node (AVN). It is the first time to report an intraoperative AVN-pacing related-WP in a patient with persistent AF. The enlarged atrium might be convenient for capturing the AVN. There are some other potential explanations for this phenomenon. The diameters of atriums decreased significantly, and the symptoms improved after the procedure. This is the first reported case in which we might achieve AVN capture in a patient with persistent AF. Although we ultimately chose HBP for better long-term pacing thresholds, the result of this case suggested that AVN pacing may be possible.
4 June 2025 in Pacing and Clinical Electrophysiology
Objective: The aim of this study was to evaluate the feasibility and safety of conduction system pacing (CSP) in patients with right bundle branch block (RBBB) and heart failure (HF). Methods: This retrospective study included all the patients with HF and a ventricular pacing frequency of more than 40% who underwent CSP between 2018 and 2023, with all enrolled patients presenting RBBB prior to the procedure. Clinical data, including echocardiographic and electrocardiographic findings, were collected before and after the procedure, with a minimum follow-up duration of 2 years. Results: CSP was successfully performed in 78 patients (78/88, 88.63%), comprising 13 patients (13/78, 16.67%) with His-bundle pacing (HBP) and 65 patients (65/78, 83.33%) with left bundle branch pacing (LBBP). Significant improvements were observed in QRS duration (148.06 ± 17.91 ms vs. 121.87 ± 14.47 ms, p < 0.001), left ventricular ejection fraction (LVEF) (43.79% ± 11.71% vs. 46.94% ± 10.06%, p = 0.020), left ventricular end-diastolic diameter (LVEDD) (54.15 ± 7.67 mm vs. 52.71 ± 7.67 mm, = 0.016), and the New York Heart Association (NYHA) functional class (2.97 ± 0.68 vs. 1.63 ± 1.08, p = 0.001). No significant change was noted in the left atrial diameter (LAD) (44.72 ± 8.07 mm vs. 43.86 ± 8.42 mm, p = 0.114). Subgroup analysis revealed that a marked LVEF improvement was observed in patients with baseline LVEF ≤35% (30.05% ± 2.76% vs. 41.42% ± 11.61%, p = 0.001). Logistic regression analysis revealed that LVEF (OR = 0.112, 95% CI: 0.011–0.839, and p = 0.001) and ΔQRS (OR = 1.449, 95% CI: 1.292–2.445, and p = 0.021) were independent predictors of echocardiographic response. Conclusion: CSP is safe and effective for patients with RBBB and HF, with particularly notable improvements in cardiac performance among those with severely reduced LVEF.